Daré Bioscience, a pioneer for women healthcare and well-being has received $10 million in funding from ARPA-H’s Sprint for Women’s Health and this funding will help the company to work on the challenges related to women’s health.
DARE-HPV from Daré Bioscience is one of its unique kind of treatment for HPV(human papillomavirus) related cervical disease and has the potential to bring a positive disruption in the clinical HPV management and its effective treatment. As we know, most of cervical cancers are caused by HPV and according to research, around 4,000 women are dying from cancer while appx. 100,000 are still being treated for cervical precancer. Since cervical cancer requires surgery to treat so most of the medics keep a close monitoring until it reaches a later stage and remove the part of the cervix that is infected, but this can be a complex one and might lead to death.
With DARE-HPV, doctors can treat the cervical disease at an early stage as well as at a later stage making it one of the versatile treatment solutions.
Sabrina Johnson is the President and CEO of Daré Bioscience and she founded this company in the year of 2015 with an aim to improve the lives of women across the world. Daré is a biopharmaceutical company and is on a mission to market healthcare and medical solutions for women across the globe.
